Ciltacabtagene autoleucel, an investigational BCMA-directed CAR-T therapy, sustained efficacy and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma.
Recent Content
- Immune duo safely targets hard-to-treat gynecological cancers
- Toward a cure for multiple myeloma within a decade
- FDA approves Tecvayli, Darzalex Faspro in combo for hard-to-treat myeloma
- Small molecule screening identifies cytotoxic endoplasmic reticulum-associated degradation inhibitors in multiple myeloma
- AML treatment combo helps most trial patients reach remission
- The [(18)F]FDG PET/CT for prognostic stratification in multiple myeloma: A systematic review and meta-analysis
- (no title)
- Teclistamab-daratumumab snag FDA approval in multiple myeloma
- Experimental therapy outperforms approved treatment in PNET trial
- (no title)